On June 15, GenScript Biotech fell 6.07% in regular trading, trading at HKD 11.91/share, with turnover of HKD 148 million. The decline comes as geopolitical headwinds continue to weigh on CXO-related stocks following the US Department of Defense's recent designation of WuXi AppTec on its 1260H military-affiliated company list on June 8, which reignited concerns over US restrictions on Chinese biomedical enterprises.

The broader CXO sector showed mixed performance on the day, with WuXi Biologics up 0.97%, WuXi XDC up 0.92%, and WuXi AppTec down 1.42%, suggesting GenScript's outsized decline may also reflect structural factors including its valuation discount to subsidiary Legend Biotech and ongoing market concerns over commercial execution risks in CAR-T therapy scaling. Despite a brief sector rebound on June 13 and positive LB2501 clinical proof-of-concept data released on June 14, policy uncertainty and fund outflows from Hong Kong-listed biotech names continue to dominate short-term sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)